Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model

BackgroundAngiogenesis is the formation of neovasculature from a pre-existing vascular network. Progression of solid tumors including lung cancer is angiogenesis-dependent. We previously introduced a bioinformatics-based methodology to identify endogenous anti-angiogenic peptide sequences, and validated these predictions in vitro in human umbilical vein endothelial cell (HUVEC) proliferation and migration assays.MethodsOne family of peptides with high activity is derived from the α-fibrils of type IV collagen. Based on the results from the in vitro screening, we have evaluated the ability of a 20 amino acid peptide derived from the α5 fibril of type IV collagen, pentastatin-1, to suppress vessel growth in an angioreactor-based directed in vivo angiogenesis assay (DIVAA). In addition, pentastatin-1 suppressed tumor growth with intraperitoneal peptide administration in a small cell lung cancer (SCLC) xenograft model in nude mice using the NCI-H82 human cancer cell line.ResultsPentastatin-1 decreased the invasion of vessels into angioreactors in vivo in a dose dependent manner. The peptide also decreased the rate of tumor growth and microvascular density in vivo in a small cell lung cancer xenograft model.ConclusionsThe peptide treatment significantly decreased the invasion of microvessels in angioreactors and the rate of tumor growth in the xenograft model, indicating potential treatment for angiogenesis-dependent disease, and for translational development as a therapeutic agent for lung cancer.

[1]  K. O'Byrne,et al.  Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. , 2000, Lung cancer.

[2]  F. Shepherd,et al.  Small cell lung cancer and targeted therapies , 2007, Current opinion in oncology.

[3]  S. Kennel,et al.  Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes. , 1994, Experimental cell research.

[4]  Horst Traupe,et al.  Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. , 2009, Neoplasia.

[5]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[6]  S. Ramalingam,et al.  Role of bevacizumab for the treatment of non-small-cell lung cancer. , 2007, Future oncology.

[7]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[8]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[9]  A. Popel,et al.  Identification of novel short peptides derived from the α4, α5, and α6 fibrils of type IV collagen with anti-angiogenic properties , 2007 .

[10]  Ranjit K. Goudar,et al.  Hypoxia, angiogenesis, and lung cancer , 2008, Current oncology reports.

[11]  R. Ge,et al.  Developing antiangiogenic peptide drugs for angiogenesis-related diseases. , 2007, Current pharmaceutical design.

[12]  J. Kawabe,et al.  Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts. , 2008, International journal of oncology.

[13]  S. T. Pottratz,et al.  Pneumocystis carinii attachment increases expression of fibronectin-binding integrins on cultured lung cells , 1994, Infection and immunity.

[14]  A. Popel,et al.  Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties. , 2007, Biochemical and biophysical research communications.

[15]  R. Herbst,et al.  Angiogenesis inhibition in the treatment of lung cancer. , 2006, Clinical advances in hematology & oncology : H&O.

[16]  A. Popel,et al.  Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. , 2009, Neoplasia.

[17]  T. Salo,et al.  Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor. , 2008, Experimental cell research.

[18]  R. Kalluri,et al.  Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity , 2008, Proceedings of the National Academy of Sciences.

[19]  E. Brambilla,et al.  p53 and lung cancer. , 1997, Pathologie-biologie.

[20]  S. Kennel,et al.  Expression of β1, β3, β4, and β5 Integrins by Human Lung Carcinoma Cells of Different Histotypes , 1994 .

[21]  R. Stupp,et al.  Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. , 2009, Neuro-oncology.

[22]  Emmanouil D Karagiannis,et al.  A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells , 2008, Proceedings of the National Academy of Sciences.